MIR585 Gene

HGNC Family Non-coding RNAs
Name microRNA 585
Description microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009]
Summary
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nmiR‐585 is emerging as a critical tumor suppressor whose reduced expression has been reported in multiple malignancies. In non‐small cell lung cancer, gastric cancer, cervical cancer, triple‐negative breast cancer, and ovarian cancer, down‐regulation of miR‐585 is associated with enhanced cell proliferation, migration, and invasion, as well as with poorer clinical outcomes. In these contexts, the deregulation of non‐coding RNAs further underscores the importance of miR‐585 in tumor biology."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "6"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nMechanistic investigations have begun to elucidate how miR‐585 exerts its tumor‐suppressive effects. In gastric cancer, miR‐585 directly targets MAPK1 to inhibit the MAPK signaling cascade, whereas in ovarian cancer, miR‐585 targets FSCN1, leading to reduced ERK phosphorylation and suppression of tumor growth. Moreover, studies in high-grade serous ovarian carcinoma are exploring the detailed molecular underpinnings of miR‐585–mediated carcinogenesis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}, {"type": "fg_f", "ref": "7"}, {"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nCollectively, these findings highlight miR‐585 as a promising prognostic biomarker and potential therapeutic target across a spectrum of cancers. While its down-regulation correlates with tumor aggressiveness and poor patient prognosis in diverse settings—including non-small cell lung, cervical, and triple-negative breast cancers—further studies are warranted to fully delineate its molecular mechanisms and validate its clinical utility in cancer management."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}, {"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "X Ding, Y Yang, Y Sun, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Transl Oncol (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s12094-016-1562-5"}], "href": "https://doi.org/10.1007/s12094-016-1562-5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27743168"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27743168"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Lei Hu, Huo Wu, Xiao Wan, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-585 suppresses tumor proliferation and migration in gastric cancer by directly targeting MAPK1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biochem Biophys Res Commun (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.bbrc.2018.03.116"}], "href": "https://doi.org/10.1016/j.bbrc.2018.03.116"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29550487"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29550487"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Yongpan Xu, Ming Dong, Jiehong Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC01436 Inhibited miR-585-3p Expression and Upregulated MAPK1 Expression to Promote Gastric Cancer Progression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Dig Dis Sci (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s10620-020-06487-w"}], "href": "https://doi.org/10.1007/s10620-020-06487-w"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32820394"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32820394"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Yumei Qi, Yo-Liang Lai, Pei-Chun Shen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification and validation of a miRNA-based prognostic signature for cervical cancer through an integrated bioinformatics approach."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Sci Rep (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41598-020-79337-4"}], "href": "https://doi.org/10.1038/s41598-020-79337-4"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33335254"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33335254"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Minya Yao, Shuqian Wang, Luyan Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Research on correlations of miR-585 expression with progression and prognosis of triple-negative breast cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Exp Med (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s10238-021-00704-0"}], "href": "https://doi.org/10.1007/s10238-021-00704-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33826023"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33826023"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Yunwei Wang, Ming Li, Jiaoxia Zeng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-585-5p impedes gastric cancer proliferation and metastasis by orchestrating the interactions among CREB1, MAPK1 and MITF."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Front Immunol (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3389/fimmu.2022.1008195"}], "href": "https://doi.org/10.3389/fimmu.2022.1008195"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "36268034"}], "href": "https://pubmed.ncbi.nlm.nih.gov/36268034"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Xiaoyuan Lu, Guilin Li, Sicong Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Ovarian Res (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/s13048-021-00841-w"}], "href": "https://doi.org/10.1186/s13048-021-00841-w"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34238324"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34238324"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Yiming Jia, Jingru Li, Jinfeng Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Study on the Function and Mechanism of miR-585-3p Inhibiting the Progression of Ovarian Cancer Cells by Targeting FSCN1 to Block the MAPK Signaling Pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Anal Cell Pathol (Amst) (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1155/2022/1732365"}], "href": "https://doi.org/10.1155/2022/1732365"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35602576"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35602576"}]}]}]}
Synonyms MIRN585, HSA-MIR-585, MIR-585
NCBI Gene ID 693170
API
Download Associations
Predicted Functions View MIR585's ARCHS4 Predicted Functions.
Co-expressed Genes View MIR585's ARCHS4 Predicted Functions.
Expression in Tissues and Cell Lines View MIR585's ARCHS4 Predicted Functions.

Functional Associations

MIR585 has 206 functional associations with biological entities spanning 4 categories (molecular profile, functional term, phrase or reference, cell line, cell type or tissue, gene, protein or microRNA) extracted from 12 datasets.

Click the + buttons to view associations for MIR585 from the datasets below.

If available, associations are ranked by standardized value

Dataset Summary
CCLE Cell Line Gene CNV Profiles cell lines with high or low copy number of MIR585 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset.
ChEA Transcription Factor Binding Site Profiles transcription factor binding site profiles with transcription factor binding evidence at the promoter of MIR585 gene from the CHEA Transcription Factor Binding Site Profiles dataset.
ChEA Transcription Factor Targets transcription factors binding the promoter of MIR585 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset.
COSMIC Cell Line Gene CNV Profiles cell lines with high or low copy number of MIR585 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset.
ENCODE Histone Modification Site Profiles histone modification site profiles with high histone modification abundance at MIR585 gene from the ENCODE Histone Modification Site Profiles dataset.
ENCODE Transcription Factor Binding Site Profiles transcription factor binding site profiles with transcription factor binding evidence at the promoter of MIR585 gene from the ENCODE Transcription Factor Binding Site Profiles dataset.
ENCODE Transcription Factor Targets transcription factors binding the promoter of MIR585 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset.
GeneSigDB Published Gene Signatures PubMedIDs of publications reporting gene signatures containing MIR585 from the GeneSigDB Published Gene Signatures dataset.
JASPAR Predicted Transcription Factor Targets transcription factors regulating expression of MIR585 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset.
Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles cell lines with high or low copy number of MIR585 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset.
MotifMap Predicted Transcription Factor Targets transcription factors regulating expression of MIR585 gene predicted using known transcription factor binding site motifs from the MotifMap Predicted Transcription Factor Targets dataset.
Roadmap Epigenomics Histone Modification Site Profiles histone modification site profiles with high histone modification abundance at MIR585 gene from the Roadmap Epigenomics Histone Modification Site Profiles dataset.